CL2020001394A1 - Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. - Google Patents

Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.

Info

Publication number
CL2020001394A1
CL2020001394A1 CL2020001394A CL2020001394A CL2020001394A1 CL 2020001394 A1 CL2020001394 A1 CL 2020001394A1 CL 2020001394 A CL2020001394 A CL 2020001394A CL 2020001394 A CL2020001394 A CL 2020001394A CL 2020001394 A1 CL2020001394 A1 CL 2020001394A1
Authority
CL
Chile
Prior art keywords
sglt
inhibitor
combination
endothelin
treatment
Prior art date
Application number
CL2020001394A
Other languages
English (en)
Inventor
Marc Bellet
Marc Iglarz
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2020001394A1 publication Critical patent/CL2020001394A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe al compuesto aprocitentán, {5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il}-sulfamida y su uso como antagonista del receptor de endotelina, en combinación con un inhibidor de SGLT-2. Además, describe composiciones farmacéuticas que comprenden aprocitentán en combinación con dicho inhibidor de SGLT-2. La invención se refiere adicionalmente a dichas composiciones farmacéuticas que comprenden formas cristalinas de aprocitentán.
CL2020001394A 2017-11-30 2020-05-27 Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. CL2020001394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017081050 2017-11-30

Publications (1)

Publication Number Publication Date
CL2020001394A1 true CL2020001394A1 (es) 2020-10-16

Family

ID=64606962

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001394A CL2020001394A1 (es) 2017-11-30 2020-05-27 Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.

Country Status (18)

Country Link
US (1) US20210169881A1 (es)
EP (1) EP3716979A1 (es)
JP (2) JP7404235B2 (es)
KR (1) KR20200094187A (es)
CN (1) CN111405899A (es)
AU (1) AU2018376263A1 (es)
BR (1) BR112020010831A2 (es)
CA (1) CA3083327A1 (es)
CL (1) CL2020001394A1 (es)
EA (1) EA202091324A1 (es)
IL (1) IL274943A (es)
MA (1) MA51203A (es)
MX (1) MX2020005543A (es)
PH (1) PH12020550745A1 (es)
SG (1) SG11202004862XA (es)
TW (1) TWI809009B (es)
UA (1) UA127083C2 (es)
WO (1) WO2019106066A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017400276B2 (en) 2017-02-27 2024-01-11 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
US11723929B2 (en) 2017-06-13 2023-08-15 The Regents Of The University Of California Methods of improving cell-based therapy
EP4054556A4 (en) * 2019-11-07 2023-11-29 Increvet, Inc. SODIUM-GLUCOSE TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY FAILURE, HYPERTENSION AND HEART FAILURE IN PETS
AU2020378025A1 (en) * 2019-11-07 2022-06-23 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Aprocitentan, preparation method therefor and use thereof
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
CA3188345A1 (en) 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
EP4364722A1 (en) * 2021-09-02 2024-05-08 Daewoong Therapeutics Inc. Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor
JP7396579B2 (ja) 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023227490A1 (en) 2022-05-22 2023-11-30 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
WO2023227721A1 (en) 2022-05-25 2023-11-30 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2024102913A1 (en) * 2022-11-10 2024-05-16 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE60118782T2 (de) 2000-12-18 2007-01-25 Actelion Pharmaceuticals Ltd. Neue sulfamiden und deren verwendung als endothelin-antagonisten
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
WO2002068440A1 (fr) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
EP1724277A4 (en) 2004-03-04 2012-05-02 Kissei Pharmaceutical ACCOLE HETEROCYCLIC DERIVATIVE, DRUG-CONTAINING COMPOSITION THEREOF, AND THE USE THEREOF
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
WO2010138535A1 (en) 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10174010B2 (en) 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
CN107106522A (zh) 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
AU2017400276B2 (en) * 2017-02-27 2024-01-11 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Also Published As

Publication number Publication date
AU2018376263A1 (en) 2020-07-16
EP3716979A1 (en) 2020-10-07
EA202091324A1 (ru) 2020-10-05
MX2020005543A (es) 2020-08-20
JP7404235B2 (ja) 2023-12-25
CN111405899A (zh) 2020-07-10
BR112020010831A2 (pt) 2020-11-10
JP2021504423A (ja) 2021-02-15
IL274943A (en) 2020-07-30
TWI809009B (zh) 2023-07-21
PH12020550745A1 (en) 2021-04-26
MA51203A (fr) 2020-10-07
JP2024037866A (ja) 2024-03-19
UA127083C2 (uk) 2023-04-05
KR20200094187A (ko) 2020-08-06
CA3083327A1 (en) 2019-06-06
SG11202004862XA (en) 2020-06-29
TW201924685A (zh) 2019-07-01
US20210169881A1 (en) 2021-06-10
WO2019106066A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
CL2017002650A1 (es) Compuestos novedosos
CL2017003402A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
DOP2016000253A (es) Nuevos compuestos
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015002083A1 (es) Composiciones herbicidas sinergicas
GT201500247A (es) Imidazopiridazinas sustituidas
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos